Supporters of a voter initiative that could help bring cheaper prescription drugs to North Dakota are hoping a legal technicality won't keep them from getting the issue placed on the ballot.
Scientists are reporting a major advance in diagnosing tuberculosis: A new test can reveal in less than two hours, with very high accuracy, whether someone has the disease and if it's resistant to the main drug for treating it.
Editors of a top medical journal call Meridia "another flawed diet pill" and question whether it should stay on the market as a study shows it raises the risk of heart attack and stroke in people with heart problems.
Thermo Fisher Scientific Inc. announced the launch of its NESLAB ThermoFlex series of recirculating chillers. The ThermoFlex 24000 has a cooling capacity of 24,000 watts to meet the needs of customers who require a higher level of cooling performance.
Spectrum Laboratories, Inc. introduces the KrosFlo Research IIi Tangential Flow Filtration (TFF) System. When used with Spectrum’s hollow fiber filters, this compact, fully integrated system provides faster separation of proteins, cells, viruses, nanoparticles, and other macromolecules.
Geospiza and SAIC-Frederick Inc. are collaborating to adapt Geospiza’s software platform to a new generation of rapid, high-resolution gene sequencing technology to potentially accelerate cancer research and help develop treatments.
Dynavax Technologies Corporation announced a grant from the National Institute of Allergy and Infectious Diseases to take a systems biology approach to study the differences between individual responses to vaccination against the Hepatitis B virus.
A new study conducted by investigators at Harvard suggests that S-Adenosyl Methionine (SAMe), an over-the-counter dietary supplement, can be an effective, adjunctive treatment for adults with major depressive disorders.
Purdue University researchers have developed a new type of pump for drug-delivery patches that might use arrays of "microneedles" to deliver a wider range of medications than now possible with conventional patches.
Novozymes Biopharma, part of Novozymes A/S, announced that the US Food and Drug Administration Center for Biologics Evaluation and Research has accepted a Type IV Master File for its recombinant albumin, albucult.
ReVision Therapeutics Inc. announced that data from a Phase 2b trial show that fenretinide reduced the incidence of choroidal neovascularization by about 50% in patients with geographic atrophy, the most advanced form of dry age related macular degeneration.
Stromedix, Inc. announced that its lead clinical candidate STX-100 has been granted orphan drug status by the U.S. Food and Drug Administration for the treatment of idiopathic pulmonary fibrosis, an almost uniformly fatal disease.
Phase 3 safety and efficacy data comparing tapentadol extended release tablets, an investigational pain medication, to placebo in patients with moderate to severe chronic osteoarthritis knee pain have been recently published.
An affiliate of New Mountain Capital, LLC announced the completion of its acquisition of Mallinckrodt Baker, Inc. from Covidien for approximately $280 million.
Scientists have found that by neutralizing a key toxin associated with the Staphylococcus aureus bacteria, they found they could greatly reduce the damaging effects of the infection on skin and soft tissue.